Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Emx1 CRISPR/Cas9 KO Plasmid (m): sc-420169
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Emx1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Emx1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Emx1 Antibody (G-6): sc-398115
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Emx1 CRISPR/Cas9 KO Plasmid (m) | sc-420169 | 20 µg | $397.00 |
Overview
EMX1 (empty spiracles homeobox 1) is a paired-like homeobox transcription factor that functions in early telencephalic patterning and neocortical arealization during mouse embryonic development. It regulates gene expression programs controlling neural progenitor proliferation, neuronal differentiation, and cortical lamination, integrating with developmental signaling networks such as WNT/β-catenin and SHH that shape forebrain regional identity. Emx1 expression is widely used as a marker of dorsal telencephalic lineages, enabling mechanistic studies of corticogenesis and circuit assembly. Dysregulated EMX1-associated transcriptional networks are relevant to neurodevelopmental phenotypes that impact brain structure and excitatory neuron lineage specification.
Emx1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Emx1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Emx1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Emx1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Emx1 protein expression.
This CRISPR knockout system enables efficient generation of Emx1-deficient cell models for investigation of Emx1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Emx1 exon(s) critical for Emx1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Emx1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Emx1 CRISPR/Cas9 KO Plasmid (m) and Emx1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Emx1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Emx1 HDR Plasmid (m) and Emx1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Emx1 homology arms to support homology-directed repair at defined Emx1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.